$170.36 2.5 1.5%
Last Trade - 17/01/20
| Market Cap | ÂŁ10.12bn |
| Enterprise Value | ÂŁ9.39bn |
| Revenue | ÂŁ328.8m |
| Position in Universe | 658th / 6416 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).
| Last Annual | December 31st, 2018 |
| Last Interim | September 30th, 2019 |
| Incorporated | October 28, 2010 |
| Public Since | February 3, 2016 |
| No. of Shareholders: | 166 |
| No. of Employees: | 3,000 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market (Dual Listing) |
| Shares in Issue | 77,054,097 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | C/O Mourant Governance Services (Cayman),94 Solaris Avenue Camana Bay, GRAND CAYMAN, KY1-1108, Cayman Islands |
| Web | |
| Phone | +1 345 9494123 |
| Auditors | Ernst & Young Hua Ming |
